The U.S. Food and Drug Administration said on Thursday it has banned more products from drugmaker Ranbaxy Laboratories (RANB.NS) from entering the United States due to manufacturing violations. The FDA said Ranbaxy is prohibited from making and distributing pharmaceutical ingredients from its facility in Toansa, India “to prevent substandard quality products from reaching U.S. consumers.” The move follows an FDA inspection of the facility which identified significant violations of good manufacturing practices.
Help employers find you! Check out all the jobs and post your resume.
